Methods for inhibiting muscle atrophy

Patent metadata

Field	Value
Publication number	US-10668087-B2
Application number	US-201816157767-A
Country	US
Kind code	B2
Filing date	Oct 11, 2018
Priority date	Jun 6, 2011
Publication date	Jun 2, 2020
Grant date	Jun 2, 2020

Abstract

In one aspect, the invention relates to methods for treating muscle atrophy by providing to an animal in need thereof an effective amount of a compound. The compound can modulate the expression levels of multiple mRNA of a muscle atrophy signature. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

First claim

The invention claimed is:

1. A method for:
(a) increasing skeletal muscle mass;
(b) reducing skeletal muscle atrophy;
(c) increasing muscular strength;
(d) promoting muscle growth;
(e) decreasing muscle wasting; or
(f) increasing strength per unit of muscle mass

in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula:

or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof, thereby accomplishing one or more of (a)-(f), wherein the animal is not a human or a rabbit.

2. The method according to claim 1 , for increasing skeletal muscle mass, wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

3. The method according to claim 1 , for reducing skeletal muscle atrophy, wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

4. The method according to claim 1 , for increasing muscular strength, wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

5. The method according to claim 1 , for promoting muscle growth, wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

6. The method according to claim 1 , for decreasing muscle wasting, wherein the compound is:

or a stereoisomer or pharmaceutically acceptable salt thereof.

7. The method according to claim 1 , for increasing strength per unit of muscle mass, wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

8. The method according to claim 1 , comprising administering to the animal greater than 75 mg per day of the compound or stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof.

9. The method according to claim 1 , comprising administering to the animal greater than 100 mg per day of the compound or stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof.

10. The method according to claim 1 , wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

11. The method according to claim 1 , comprising administering to the animal greater than 150 mg per day of the compound or stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof.

12. The method according to claim 11 , wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

13. The method according to claim 1 , comprising administering to the animal at least 5.0 mg/kg per day of the compound or stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof.

14. The method according to claim 13 , wherein the compound is

or a stereoisomer, or pharmaceutically acceptable salt thereof.

15. The method according to claim 1 , comprising administering to the animal 0.5 to 250 mg/kg per day of the compound or stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof.

16. The method according to claim 15 , wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

17. The method according to claim 1 , wherein said animal is selected from the group consisting of a non-human primate, domesticated fish, domesticated crustacean, domesticated mollusk, poultry, dog, cat, and livestock.

18. The method according to claim 17 , wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

19. The method according to claim 1 , wherein said animal is selected from the group consisting of a non-human primate, horse, pig, dog, sheep, goat, cow, cat, guinea pig, fish, and bird.

20. The method according to claim 19 , wherein the compound is

or a stereoisomer or pharmaceutically acceptable salt thereof.

Assignees

• Univ Iowa Res Found
• Us Gov Veterans Affairs

Inventors

• Adams Christopher M
• Kunkel Steven D
• Welsh Michael

Classifications

• G01N33/5023

  on expression patterns · CPC title

• A61K31/435

  having six-membered rings with one nitrogen as the only ring hetero atom · CPC title

• A61K31/473

  ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines · CPC title

• G01N2800/10

  Musculoskeletal or connective tissue disorders · CPC title

• A61K31/36

  Compounds containing methylenedioxyphenyl groups, e.g. sesamin · CPC title